Product Portfolio

Home » Product Portfolio » publications

Publications

Avenue Therapeutics, Inc.

IV Tramadol

Scott, L. et al. Tramadol: A Review of its Use in Perioperative Pain. Adis International Limited, Drugs 2000 Jul; 60 (1): 139-176.

Caelum Biosciences, Inc.

Edwards, C. et al. Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. 58th Annual American Society of Hematology; December 2016. Abstract 643.

Edwards, C. et al. Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoconal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis. 59th Annual American Society of Hematology; 2017. Abstract 509. 

Checkpoint Therapeutics, Inc.

Anti-CAIX

Xu, C. et al. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One 5, e9625 (2010).

Chang, D.-K. et al. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol. Cancer 14, 119 (2015).

Cellvation, Inc.

Cox Jr., C. S. et al. Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells. STEM CELLS 2016. DOI: 10.1002/stem.2538.

Fortress Biotech, Inc.

CNDO-109

CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1): A Phase 1 Study. Innate Killer Summit 2016, May 17, 2016. (Oral Presentation).

Helocyte, Inc.

PepVax

Nakamura, R., et al (2016). Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: Randomised phase 1b trial. The Lancet Haematology, 3(2). doi:10.1016/s2352-3026(15)00246-x.

Triplex

Diamond D.J., et al. Safety, Maximum Tolerated Dose and Immunogenicity of CMV-MVA-Triplex in Healthy Volunteers with or without Prior Immunity to CMV and Vaccinia [abstract]. In: American Society of Hematology 57th Annual Meeting & Exposition; 2015 Dec 5-8; Orlando, FL. ASH; 2015. Abstract nr 3108.

La Rosa, C. et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T-cells in healthy adults. Blood 2016: blood-2016-07-729756. doi: 10.1182.

Pentamer

Wussow, F., et al (2014). Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex. PLoS Pathog PLoS Pathogens, 10(11). doi:10.1371/journal.ppat.1004524.

Mustang Bio, Inc.

MB-101 (IL13Rα2-specific CAR)

2016 Abstracts

Aguilar, B. et al. Optimization of IL13Rα2-specific CAR T cells for Clinical Development Using Orthotopic Human Glioblastoma Models in NSG Mice. 2016 American Society of Gene and Cell Therapy 19th Annual Meeting, May 4-7, 2016. Abstract #275.

Alizadeh, D. et al. Development of Murine IL13Rα2-Targeted CAR T Cells (mIL13BBz) for Assessment of CAR T Cell Therapy in Syngeneic Glioma Models. 21st Annual Meeting and Education Day of the Society for Neuro-Oncology, November 18, 2016. Abstract IMST-36.

Brown, C. et al. Phase I Study of Chimeric Antigen Receptor-Engineered T Cells Targeting IL13Ra2 for the Treatment of Glioblastoma. 21st Annual Meeting and Education Day of the Society for Neuro-Oncology, November 18, 2016. Abstract ATIM-13.

Brown, C. et al. Phase I Study of Second Generation Chimeric Antigen Receptor–Engineered T cells Targeting IL13Rα2 for the Treatment of Glioblastoma.  2016 American Society of Gene and Cell Therapy 19th Annual Meeting, May 4-7, 2016. Abstract #247.

Reference Articles

Brown, C. et al. Regression of Gliobastoma after Chimeric Antigen Receptor T-Cell Therapy. New England Journal of Medicine December 2016; 375: 2561-2569.

Jonnalagadda M, et al. Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. Mol Ther. 2015;23: 757–768.

MB-102 (CD123 CAR)

2017 Abstracts

Budde, L., et al. Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial. 2017; Abstract #811.

Reference Articles

Mardiros A, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013;122: 3138–3148.

Wang X, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011;118(5): 1255-1263.